RecruitingPHASE1, PHASE2NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Indapta Therapeutics, INC.
- Principal Investigator
- Indapta Therapeutics, Inc.Indapta Therapeutics, INC.
- Intervention
- IDP-023(drug)
- Enrollment
- 128 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (12)
- Valkyrie Clinical Trials, Los Angeles, California, United States
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States
- Emory University Hospital, Atlanta, Georgia, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- NYP/Weill Cornell Medical Center, New York, New York, United States
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
- University Hospitals Cleveland, Cleveland, Ohio, United States
- Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Oncology Virginia, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06119685 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics